Patents matching “antibody”

US 11827713

Chimeric antibody immune effector cell engagers and methods of use thereof

Nanjing Legend Biotech Co., Ltd · Granted Nov 28, 2023 · Expires Nov 23, 2043

US 11814439

Anti-CD20 antibody compositions

TG Therapeutics, Inc. · Granted Nov 14, 2023 · Expires Nov 9, 2043

US 11814428

Anti-PTCRA antibody-drug conjugates and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Nov 14, 2023 · Expires Nov 9, 2043

US 11813335

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA · Granted Nov 14, 2023 · Expires Nov 9, 2043

US 11807689

Anti-CD20 antibody compositions

TG Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

US 11807661

Antibody fusion protein and related compositions for targeting cancer

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Nov 7, 2023 · Expires Nov 2, 2043

US 11795234

Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

Dyne Therapeutics, Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

US 11795233

Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide

Dyne Therapeutics, Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

US 11786603

Optimized transglutaminase site-specific antibody conjugation

REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

US 11786605

Site specific antibody-drug conjugates with peptide-containing linkers

Mersana Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

US 11780930

CD38 modulating antibody

BLACK BELT THERAPEUTICS LIMITED · Granted Oct 10, 2023 · Expires Oct 5, 2043

US 11767367

Monoclonal antibody neo-201 for the treatment of human carcinomas

PRECISION BIOLOGICS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

US 11744876

Immunomodulator antibody drug conjugates and uses thereof

Sutro Biopharma, Inc. · Granted Sep 5, 2023 · Expires Aug 31, 2043

US 11725024

Antibody drug conjugates

Takeda Pharmaceutical Company Limited · Granted Aug 15, 2023 · Expires Aug 10, 2043

US 11717576

Antibody-immune agonist conjugate and applications thereof

GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Granted Aug 8, 2023 · Expires Aug 3, 2043

US 11708413

Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates

Sutro Biopharma, Inc. · Granted Jul 25, 2023 · Expires Jul 20, 2043

US 11708406

Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody

AVALO THERAPEUTICS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

US 11702473

Site-specific antibody-drug conjugates

ADC THERAPEUTICS SA · Granted Jul 18, 2023 · Expires Jul 13, 2043

US 11697689

Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs

INSTITUT DE CANCEROLOGIE DE L'OUEST · Granted Jul 11, 2023 · Expires Jul 6, 2043

US 11692027

Antibody and protein therapeutic formulations and uses thereof

The Board of Regents of the University of Texas System · Granted Jul 4, 2023 · Expires Jun 29, 2043

US 11690918

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA · Granted Jul 4, 2023 · Expires Jun 29, 2043

US 11685775

Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody

The Regents of the University of California · Granted Jun 27, 2023 · Expires Jun 22, 2043

US 11680105

Antibody fragments for detecting cancer and methods of use

Regents of the University of Minnesota · Granted Jun 20, 2023 · Expires Jun 15, 2043

US 11672872

Anti-transferrin receptor antibody and uses thereof

Dyne Therapeutics, Inc. · Granted Jun 13, 2023 · Expires Jun 8, 2043